Compare
Alnylam Pharmaceuticals vs Amgen (ALNY vs AMGN)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Alnylam Pharmaceuticals (ALNY) returned -64.1% and Amgen (AMGN) +43.9%; so far this year the figures are -60.8% and +40.7%.
Amgen is the larger company by market value, about 11.9 times the size of Alnylam Pharmaceuticals.
On trailing earnings, ALNY trades at 66.9 times and AMGN at 26.7 times.
Revenue grew +65.2% at ALNY and +8.2% at AMGN over the last year.
ALNY pays no dividend. AMGN yields 2.16%.
Data as of the latest close. Not investment advice.
Relative performance
| ALNY | AMGN | |
|---|---|---|
| Price | $155.94 | $460.42 |
| 1-day | -0.46% | +0.03% |
| YTD | -60.78% | +40.67% |
| 1 year | -64.12% | +43.94% |
| 3 years | -0.68% | +76.51% |
| Market cap | $20.9B | $249.1B |
| P/E | 66.9 | 26.7 |
| P/S | 5.62 | 6.40 |
| P/B | 5.80 | 17.35 |
| Revenue growth | +65.20% | +8.20% |
| EPS growth | — | +33.30% |
| Gross margin % | 81.8 | 70.9 |
| Net margin % | 8.4 | 24.1 |
| ROE % | 8.7 | 65.4 |
| Debt / equity | 0.19 | 3.76 |
| FCF yield % | 2.2 | 3.8 |
| Dividend yield % | — | 2.16 |
| Beta | 0.47 | 0.50 |
| RSI (14) | 21.8 | 60.5 |
| Technical rating |